Trial · NCT06146478
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
NCT06146478, Phase 3, Completed, Blood Care Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients. Trials, record NCT06146478. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06146478
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
- NCT number
- NCT06146478
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 200 participants, actual
- Lead sponsor
- Blood Care Clinic
- Conditions
- Transfusion-dependent Beta-Thalassemia
- Interventions
- Thalidomide
- First posted
- 2023-11-24
- Last updated
- 2023-11-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response to thalidomide on the basis of increase in hemoglobin (Hb) level at 12 months of treatment. | Baseline, 1 month, 6 months and 12 months | On the basis of increase in Hb level patients categorized as follows: 1. Excellent Responders (ER): In whom the Hb level raised to ≥9.0g/dl without any transfusion in the last two months. 2. Good Responders (GR): In whom the Hb level raised to 7.0-8.9 g/dL without any transfusion in the last two months. 3. Partial Responders (PR): In whom the Hb level remained \<7.0 g/dL but did raise to a significantly higher level than the base-line without any transfusion in the last two months. 4. Non-Responders (NR): In whom the Hb level did not show any significant improvement in comparison to the base-line |
| Primary | Association of different β- globin mutations with response to thalidomide | Baseline | Amplification refractory mutation system polymerase chain reaction (ARMS-PCR) is used for detection of β- globin mutations. |
| Primary | Association of Single Nucleotide Polymorphisms (SNPS) of HBG2, BCL11A and HBS1L-MYB with response to thalidomide | Baseline | PCR \& DNA Sequencing are used for SNP genotyping |
| Secondary | Change from baseline in GATA1 and KLF1 gene expression at 12 months of thalidomide treatment | Baseline and after 12 months | Real Time-Polymerase Chain Reaction (RT-PCR) is used for analysis of gene expression |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06146478
GET https://conductscience.org/api/trials/v1/NCT06146478/registered